Health breakthroughs and money matters, in plain words

Home » Biocon’s Pebrilzo FDA Approval Cements Its Role in Affordable Cancer Care

Biocon’s Pebrilzo FDA Approval Cements Its Role in Affordable Cancer Care

By

–

Biocon's Pebrilzo FDA Approval Cements Its Role in Affordable Cancer Care

Biocon has received US Food and Drug Administration approval for Pebrilzo, a biosimilar to the breast cancer drug Perjeta, marking the Indian biopharmaceutical company’s fifth oncology biosimilar cleared for the American market. The approval, dated November 12, 2026, comes alongside a global settlement with Genentech that sets a licensed US launch for the third quarter of 2028 and an earlier entry in Europe and the United Kingdom by the first quarter of 2027.

What Pebrilzo Is and Who It Helps

Pebrilzo (pertuzumab-qcay) is a monoclonal antibody designed to treat HER2-positive breast cancer, a form of the disease that affects roughly one in five of the approximately 320,000 women diagnosed with breast cancer in the US each year. The drug works by blocking HER2 receptors on cancer cells, slowing or stopping tumor growth. It is indicated for use in combination with trastuzumab and chemotherapy for both early-stage and metastatic HER2-positive breast cancer.

For families navigating this diagnosis, the burden stretches far beyond the physical toll. Biocon CEO Shreehas Tambe noted that the disease often places “considerable financial strain on patients and their families,” and framed the approval as a step toward “expanding access to high-quality, affordable biologic medicines.”

The Path to Market: Settlement Over Litigation

Regulatory approval alone does not guarantee a drug reaches pharmacy shelves. Biocon’s biologics license application (BLA #761501) was approved on November 12, but patent disputes with Genentech, the maker of the reference product Perjeta, stood in the way of commercial launch. Genentech had filed a patent-infringement case in a New Jersey court, which was dismissed at Genentech’s request following a global settlement and license agreement covering the US, Canada, and other jurisdictions.

The agreement establishes defined entry dates: Q1 2027 for the European Union and United Kingdom, where the European Medicines Agency’s CHMP issued a positive opinion recommending marketing authorization in September, and Q3 2028 for the United States. Commercial terms, including any royalty arrangements or settlement payments, remain confidential.

A Growing Portfolio for Affordable Cancer Care

With Pebrilzo, Biocon now holds five USFDA-approved oncology biosimilars. The existing portfolio includes Ogivri (trastuzumab-dkst), Jobevne (bevacizumab-nwgd), Fulphila (pegfilgrastim-jmdb), and Aukelso (denosumab-kyqq). The company, founded in 1978 by Kiran Mazumdar-Shaw and headquartered in Bengaluru with US operations in Bridgewater, New Jersey, has built a reputation for manufacturing biosimilars sold in bulk and formulation forms across emerging markets. Its production of generics has been credited with saving European healthcare systems an estimated €30 billion in drug costs as of 2022.

The pipeline continues to expand, with proposed biosimilars targeting trastuzumab/hyaluronidase, nivolumab, and pembrolizumab in development.

What This Means for Patients

Biosimilars are designed to be highly similar to approved reference biologics, offering the same clinical benefit at a lower cost. The Perjeta reference product has been a standard of care for HER2-positive breast cancer, but its price has been a barrier for many. The entry of Pebrilzo into the market, once launched, is expected to introduce competition that could lower out-of-pocket costs for patients and reduce spending for insurers and health systems.

The timeline, however, requires patience. While the European launch could begin as early as Q1 2027, US patients will wait until Q3 2028. As always, treatment decisions should be made in consultation with an oncologist.

Sources

Photo: Sofia Negron (CC BY-SA 3.0)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News